Fighting Cancer with
A Single Draw of Blood
Cutting-edge genomic tests for cancer detection and treatment selection.
Ultrasensitive and Non-invasive
As a part of our efforts against COVID-19 , we applied our expertise in molecular diagnostics and developed solutions to improve testing. University study reports 36% greater detection of SARS-CoV-2 using SAFER™ Saliva Collection Kit compared to standard swabs, achieving more accurate, accessible, and affordable testing.
Every cancer is different.
So is our approach.
No two people are the same, and neither are cancer tumors. The first step to smarter fighting cancer begins with uncovering the mutations that drive each person’s cancer. Precision medicine utilizes genomic information to tailor diagnoses and treatments to each patient’s cancer.
LiquidHALLMARK® detects cancer-driving gene mutations and viruses in each patient’s tumor from a single blood draw, allowing physicians to make more informed decision for their patients’ care.
Genomic Medicine: The future of cancer fighting
AmpliMARK™ - Our proprietary, ultrasensitive platform that advanced sequencing technology for cancer diagnostics
To transform cancer care, we continually research and invent new technologies and solutions